The ABCG2 resistance network of glioblastoma

Cell Cycle

Volumn 8, Issue 18, 2009, Pages 2937-2945

  Bleau, Anne Marie ^a   Huse, Jason T ^a   Holland, Eric C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Blood brain barrier; Cancer stem like cells; Genetic alterations; Glioblastoma; Microenvironment; Resistance

Indexed keywords

AXITINIB; BEVACIZUMAB; BREAST CANCER RESISTANCE PROTEIN; CARMUSTINE; CD133 ANTIGEN; ERLOTINIB; MULTIDRUG RESISTANCE PROTEIN 1; PAZOPANIB; RANIBIZUMAB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE;

ANTIANGIOGENIC THERAPY; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL INVASION; CELL SURVIVAL; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; HYPOXIA; MISMATCH REPAIR; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 70349296853     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.18.9504     Document Type: Review

References (74)

1. Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 2004; 6:433-438 (Pubitemid 39469978)
2. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-1068
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica 2007; 114:97-109.
4. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 2005; 11:6767-6771 (Pubitemid 41428729)
5. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10:3728-3736 (Pubitemid 38697606)
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009.
7. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26:4189-4199
8. Ingold B, Schraml P, Heppner FL, Moch H. Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS ONE 2009; 4:4775.
9. Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, et al. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 2008; 87:71-78
10. Huang F, Kavan P, Guiot MC, Markovic Y, Roberge D. When temozolomide alone fails: adding procarbazine in salvage therapy of glioma. Can J Neurol Sci 2008; 35:192-197 (Pubitemid 351831056)
11. Glas M, Happold C, Rieger J, Wiewrodt D, Bahr O, Steinbach JP, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009; 27:1257-1261
12. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009; 27:579-584
13. Hambardzumyan D, Becher OJ, Holland EC. Cancer stem cells and survival pathways. Cell cycle (Georgetown, Tex) 2008; 7:1371-1378 (Pubitemid 351872575)
14. Zhou J, Zhang Y. Cancer stem cells: Models, mechanisms and implications for improved treatment. Cell Cycle 2008; 7:1360-1370 (Pubitemid 351872574)
15. Harris MA, Yang H, Low BE, Mukherje J, Guha A, Bronson RT, et al. Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res 2008; 68:10051-10059
16. Balenci L, Clarke ID, Dirks PB, Assard N, Ducray F, Jouvet A, et al. IQGAP1 protein specifies amplifying cancer cells in glioblastoma multiforme. Cancer Res 2006; 66:9074-9082 (Pubitemid 44521126)
17. - tumor-initiating cells in adult human gliomas. Neurosurgery 2008; 62:505-514
18. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401. (Pubitemid 39551674)
19. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004; 23:9392-9400 (Pubitemid 40069671)
20. Bleau AM, Howard BM, Taylor LA, Gursel D, Greenfield JP, Lim Tung HY, et al. New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans. Neurosurg Focus 2008; 24:28.
21. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009; 4:226-235
22. Currle DS, Gilbertson RJ. The niche revealed. Cell Stem Cell 2008; 3:234-236
23. Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999; 97:703-716 (Pubitemid 29278045)
24. Diamandis P, Sacher AG, Tyers M, Dirks PB. New drugs for brain tumors? Insights from chemical probing of neural stem cells. Med Hypotheses 2009; 72:683-687
25. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005; 8:119-130 (Pubitemid 41132741)
26. Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009; 15:45-56.
27. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, VandenBerg S, et al. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 2006; 51:187-199 (Pubitemid 44063617)
28. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005; 8:323-335 (Pubitemid 41443417)
29. Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, Aldape KD, et al. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res 2007; 67:890-900. (Pubitemid 46270742)
30. Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, Holland EC. Modeling adult gliomas using RCAS/t-va technology. Transl Oncol 2009; 2:89-95.
31. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005; 45:872-877 (Pubitemid 41060226)
32. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002; 99:507-512 (Pubitemid 34533085)
33. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nature Rev 2005; 5:275-284 (Pubitemid 40488633)
34. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183:1797-1806 (Pubitemid 26134320)
35. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008; 268:1-9.
36. - cancer cells are similarly tumorigenic. Cancer Res 2005; 65:6207-6219
37. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101:14228-14233
38. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67:4827-4833 (Pubitemid 46910191)
39. Orford M, Mean R, Lapathitis G, Genethliou N, Panayiotou E, Panayi H, et al. Generation of an ABCG2 (GFPn-puro) transgenic line - A tool to study ABCG2 expression in mice. Biochem Biophys Res Commun 2009; 384:199-203.
40. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-760 (Pubitemid 44949604)
41. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14:8205-8212
42. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67:4010-4015 (Pubitemid 46815044)
43. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008; 122:761-768
44. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008; 68:5706-5715
45. Huang Q, Zhang QB, Dong J, Wu YY, Shen YT, Zhao YD, et al. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer 2008; 8:304.
46. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008; 26:3015-3024
47. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008; 455:1129-1133
48. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE 2008; 3:3769.
49. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007; 53:503-517 (Pubitemid 46216748)
50. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008; 68:6043-6048
51. Jeon HM, Jin X, Lee JS, Oh SY, Sohn YW, Park HJ, et al. Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev 2008; 22:2028-2033
52. Wang Z, Li Y, Banerjee S, Sarkar FH. Emerging role of Notch in stem cells and cancer. Cancer Lett 2009; 279:8-12.
53. Shih AH, Holland EC. Notch signaling enhances nestin expression in gliomas. Neoplasia 2006; 8:1072-1082
54. Bhattacharya S, Das A, Mallya K, Ahmad I. Maintenance of retinal stem cells by Abcg2 is regulated by notch signaling. J Cell Sci 2007; 120:2652-2662 (Pubitemid 47323873)
55. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66:7445-7452 (Pubitemid 44289197)
56. Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol 2007; 3:268-273 (Pubitemid 46625832)
57. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008; 22:436-448 (Pubitemid 351272752)
58. Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (Dayton, Ohio) 2008; 26:3027-3036
59. Bernacki J, Dobrowolska A, Nierwinska K, Malecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008; 60:600-622
60. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5:219-234
61. Shukla S, Wu CP, Ambudkar SV. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 2008; 4:205-223 (Pubitemid 351308418)
62. Mouthon MA, Fouchet P, Mathieu C, Sii-Felice K, Etienne O, Lages CS, et al. Neural stem cells from mouse forebrain are contained in a population distinct from the 'side population'. J Neurochem 2006; 99:807-817
63. Provenzale JM, Mukundan S, Dewhirst M. The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. AJR Am J Roentgenol 2005; 185:763-767
64. McConville P, Hambardzumyan D, Moody JB, Leopold WR, Kreger AR, Woolliscroft MJ, et al. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res 2007; 13:2897-2904 (Pubitemid 46849564)
65. Tavazoie M, Van der Veken L, Silva-Vargas V, Louissaint M, Colonna L, Zaidi B, et al. A specialized vascular niche for adult neural stem cells. Cell Stem Cell 2008; 3:279-288
66. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11:69-82. (Pubitemid 46054518)
67. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev 2008; 8:592-603.
68. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231
69. 2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci USA 2005; 102:4783-4788
70. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr, Gillespie GY. CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE 2008; 3:3655.
71. Krishnamurthy P, Ross DD, Nakanishi T, Bailey- Dell K, Zhou S, Mercer KE, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004; 279:24218-24225 (Pubitemid 38725283)
72. Martin CM, Ferdous A, Gallardo T, Humphries C, Sadek H, Caprioli A, et al. Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells. Circ Res 2008; 102:1075-1081 (Pubitemid 351667861)
73. Tavaluc RT, Hart LS, Dicker DT, El-Deiry WS. Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle 2007; 6:2554-2562
74. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15:501-513